Abstracts tagged "Efficacy"

Abstract Number: 1815 • ACR Convergence 2021
Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
yan li¹, Kunpeng Li¹, Zheng Zhao¹, yanyan wang¹, Jingyu Jin¹, jianglin zhang¹, Jian Zhu¹ and feng huang², ¹First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, China (People's Republic), ²Chinese PLA General Hospital, Beijing, China (People's Republic)
Background/Purpose: Iguratimod, also known as T-614, is a new type of small molecule compound with anti-inflammatory and immunomodulatory effects; It was listed in China(2011) and…
Abstract Number: 1819 • ACR Convergence 2021
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
Arthur Kavanaugh¹, Siba Raychaudhuri², Christopher Ritchlin³, Akihiko Asahina⁴, Proton Rahman⁵, Fred Murphy⁶, Stephen Rozzo⁷, Siu-Long Yao⁷, Richard C Chou⁸ and Elaine Husni⁹, ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, Sacramento, CA, ³Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁵Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁸University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, Buffalo, NY, ⁹Cleveland Clinic, Cleveland, OH
Background/Purpose: Metabolic syndrome (MetS) is a combination of specific risk factors for cardiovascular disease.1 The prevalence of MetS in patients (pts) with PsA has been…
Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].